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sensitivity of 18F-labelled sodium ﬂuoride in conjunction with positron emission tomography/computed tomography (18F-
NaF PET/CT) for detecting RCC bone metastases, compared with conventional imaging by bone scintigraphy or CT.
Patients and methods: An adaptive two-stage trial design was utilized, which was stopped after the ﬁrst stage due to
statistical efﬁcacy. Ten patients with stage IV RCC and bone metastases were imaged with 18F-NaF PET/CT and 99mTc-
labelled methylene diphosphonate (99mTc-MDP) bone scintigraphy including pelvic single photon emission computed
tomography (SPECT). Images were reported independently by experienced radiologists and nuclear medicine physicians
using a 5-point scoring system.
Results: Seventy-seven lesions were diagnosed as malignant: 100% were identiﬁed by 18F-NaF PET/CT, 46% by CT
and 29% by bone scintigraphy/SPECT. Standard-of-care imaging with CT and bone scintigraphy identiﬁed 65% of the
metastases reported by 18F-NaF PET/CT. On an individual patient basis, 18F-NaF PET/CT detected more RCC metasta-
ses than 99mTc-MDP bone scintigraphy/SPECT or CT alone (P = 0.007). The metabolic volumes, mean and maximum
standardized uptake values (SUVmean and SUVmax) of the malignant lesions were signiﬁcantly greater than those of the
benign lesions (P < 0.001).
Conclusions: 18F-NaF PET/CT is signiﬁcantly more sensitive at detecting RCC skeletal metastases than conventional
bone scintigraphy or CT. The detection of occult bone metastases could greatly alter patient management, particularly in
the context when standard-of-care imaging is negative for skeletal metastases.
Key words: renal cell carcinoma, bone metastases, 18F-NaF PET/CT, 99mTc-MDP bone scintigraphy, computed
tomography
introduction
Renal cell carcinoma (RCC) is the 13th most common cancer
worldwide with an estimated 63 920 new cases in the United
States in 2014 and patients may have advanced or unresectable
disease at presentation [1]. Approximately a third of patients
with RCC develop bone metastases and these may cause signiﬁ-
cant morbidity including pain, loss of mobility, spinal cord
compression, hypercalcaemia and pathological fractures [2].
Thirty percent of patients treated by nephrectomy with cura-
tive intent for localized RCC develop metastatic disease on
follow-up, which may result from occult metastases that were
present at the time of surgery [2]. Therefore, optimized pre-
operative detection and localization of metastases is important
for guiding management. A sensitive test for bone metastases
could help avoid unnecessary surgery in patients with metastatic
disease, or allow solitary lesions to be surgically resected when
additional metastases are conﬁdently excluded [3]. In addition,
recent advances in the medical management of patients with
advanced RCC require companion imaging biomarkers to ac-
curately assess disease and monitor drug efﬁcacy [4].
Current practice for imaging patients with RCC is contrast-
enhanced computed tomography (CT) of the thorax, abdomen
and pelvis in combination with 99mTc-labelled methylene
diphosphonate (99mTc-MDP) skeletal scintigraphy, if there are
features to suggest bone metastases. Since bone lesions from
RCC are often lytic with a poor osteoblastic response, there may
be limited uptake of the 99mTc-MDP tracer. Multidetector CT
has been reported to have a sensitivity of only 66% for vertebral
metastases and a recent meta-analysis found a sensitivity of only
59% for the detection of bone metastases with bone scintigraphy
across a range of cancers [5, 6]. More sensitive tests for detecting
bone metastases are therefore required.
18Fluorine-labelled sodium ﬂuoride (18F-NaF) is a highly sen-
sitive positron emission tomography (PET) tracer for detection
of increased bone turnover, which occurs within the metastases
of many tumors [7, 8]. 18F-NaF was originally used as an agent
for skeletal scintigraphy with a standard gamma camera, before
it was superseded by 99mTc-MDP. However, with the improved
availability of PET technology, 18F-NaF has re-emerged as an
agent for skeletal imaging [7, 8], and the combination of 18F-
NaF PET imaging with CT enables accurate anatomical localiza-
tion of 18F uptake. Despite the promising role of 18F-NaF PET/
CT in other cancers, there are limited data demonstrating the
diagnostic performance of the technique for RCC metastases [9,
10]. We present a prospective study of patients with known
RCC bone metastases, comparing the sensitivity of 18F-NaF
PET/CT to 99mTc-MDP bone scintigraphy [including pelvic
single photon emission computed tomography (SPECT)] and
CT alone. The primary aim was to identify whether 18F-NaF
PET/CT has increased sensitivity for the detection of occult
bone metastases compared with current standard-of-care
imaging and consequently whether it may have a role in the
routine management of patients with the disease.
patients andmethods
The trial was undertaken with ethical and institutional approval as a Clinical
Trial of an Investigative Medicinal Product under the Medicines and
Healthcare Products Regulatory Agency. Patients with metastatic (stage IV),
pathologically conﬁrmed RCC were recruited from the renal oncology clinic
between May 2012 and August 2013. All tumor subtypes were included.
Patients either had conﬁrmed bone metastases (diagnosed by standard-of-
care bone scintigraphy or CT) or suspected bone metastases (with bone
pain, bone mass or neurological symptoms likely due to bone metastases).
imaging
99mTc-MDP bone scintigraphy was carried out 3 h after i.v. administration
of 600 MBq 99mTc-MDP. Anterior and posterior whole-body planar bone
scintigrams were acquired from vertex to toes using a Discovery NM630
SPECT or 670 SPECT/CT system (GE Healthcare) ﬁtted with high-reso-
lution, low-energy collimators. Images were acquired over 15 min. SPECT
imaging of the pelvis was carried out over 25 min using a 128 × 128 matrix
and a 50 × 40 cm ﬁeld of view. SPECT images were reconstructed and dis-
played as transverse and orthogonal slices. The pelvis was selected for
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additional imaging given the difﬁculty of discriminating overlapping struc-
tures in this region on planar imaging.
18F-NaF PET/CT imaging of the whole body was carried out 60 min after
i.v. administration of 250 MBq 18F-NaF using a Discovery 690 PET/CT
system (GE Healthcare). The 18F-NaF was manufactured by the Wolfson
Brain Imaging Centre, University of Cambridge, as an Investigational
Medicinal Product. An initial unenhanced high-resolution CT was carried
out from vertex to toes, which was subsequently used for attenuation correc-
tion of the PET data. CT images were acquired at 120 kV with variable mA
and a slice thickness of 3.75 mm and reconstructed using soft tissue and
bone algorithms. PET imaging was carried out with a total of 12–15 bed
positions (3 min/position). The PET images were fused with the CT images
on an Advantage workstation (GE Healthcare) and displayed individually
and together as transverse and orthogonal slices.
reporting
Each imaging modality was reported independently by a single radiologist/
nuclear medicine physician with ≥5 years’ experience in reporting as an
attending/consultant, using a routine clinical workstation (GE Healthcare).
Each lesion was reported with a malignancy certainty score from 1 to 5 (sup-
plementary Table S1, available at Annals of Oncology online). Discriminating
features included increased/decreased tracer uptake, location, pattern, size
and aggressive appearance.
Lesions identiﬁed on 99mTc-MDP bone scintigraphy or SPECT were
recorded as having either low/high tracer uptake. Lesions identiﬁed by CT
were reported as lytic (low attenuation) or sclerotic (high attenuation).
Lesions identiﬁed by 18F-NaF PET/CT were recorded as having low or high
tracer uptake, or as only visible on the CT element of the PET/CT. The time
to report each study was also recorded.
Given the dual nature of PET/CT, lesions reported as malignant by the
radiologist (scoring 4–5) were reviewed by a nuclear medicine physician
who also gave a certainty score for malignancy and these scores were then
averaged.
The initial imaging reports were used for the primary analysis. Following
this, the reporters discussed the lesions with discrepancies between the mo-
dalities. Lesions associated with surgical interventions were excluded due to
difﬁculty in discriminating a benign response to intervention, from residual
or recurrent malignant disease. Certainty scores were adjusted for some
lesions following multimodality team discussion, as would occur in the
setting of a tumor board or multidisciplinary team meeting. Reports were
adjusted to include all lesions identiﬁed by each modality. The secondary
analysis was carried out on these consensus data. Follow-up imaging was
reviewed by searching the hospital image archive for subsequent standard-
of-care imaging.
The lesions with 18F-NaF uptake were quantitatively analyzed using pro-
prietary software (Advantage Workstation, GE Healthcare). A threshold of
75% of the SUVmax was used to calculate the SUVmean and the metabolic
volume deﬁned by this threshold was recorded.
statistics
The trial was powered to answer two primary research questions: whether
18F-NaF PET/CT detected more lesions than bone scintigraphy or CT alone,
using the median number of lesions identiﬁed with each technique. A multi-
arm multistage design was used: 10 patients in the ﬁrst stage and 10 in the
second if necessary [11]. The futility and efﬁcacy boundaries in the ﬁrst stage
were P values above 0.15 and below 0.05, respectively. For each hypothesis,
the trial design had a 90% power with a 5% one-sided type I error rate where
PET/CT provides an increase in the mean number of lesions detected from 2
to 3.5. As recommended for exploratory trials, we did not correct for the two
primary hypotheses [12]. The maximum chance of making a type I error
was 10%.
Lesions with a certainty score of 4–5 were considered malignant. Any
lesion reported as malignant by one or more modality was presumed to re-
present a metastasis. To test the two primary research questions, a one-sided
Wilcoxon-signed rank test was used (www.r-project.org). A Poisson general-
ized mixed-effects regression was used as a secondary analysis to test the dif-
ference in the mean number of lesions found; ﬁxed effects for the modality
used and random effects for each individual were included.
For analysis of the metabolic volume, SUVmean and SUVmax of the benign
and malignant lesions, a linear mixed-effects model was ﬁtted with a
random effect for each individual. In each case, the outcome variable was
transformed to the log-scale to ensure homoscedasticity. The model para-
meters were used to derive P values testing the difference in mean metabolic
volume, SUVmean and SUVmax between malignant and benign lesions.
results
Eleven patients were enrolled in the trial, but one withdrew due
to discomfort during the 18F-NaF PET/CT imaging, leaving a
total of 10 participants (Table 1). Follow-up imaging was
reviewed for up to 2 years after the study imaging, with a
minimum of 2 months (due to patient death). Three patients
died during the trial.
imaging outcomes
Based on the initial reports, 18F-NaF PET/CT detected more
RCC metastases than 99mTc-MDP bone scintigraphy/SPECT or
CT alone on an individual patient basis (P = 0.0099 and 0.0098,
respectively). Since these P values were below a value of 0.05, the
trial was terminated early for efﬁcacy.
Table 1. Patient characteristics
Characteristics Number
Male 6
Female 4
Age range (years) 48–79
ECOG score 0 4
ECOG score 1 3
ECOG score 2 3
Histology 6 clear cell
1 papillary
3 unclassified, poorly
differentiated
Prestudy radiotherapy 3
Prestudy antiangiogenic agent
(pazopanib, everolimus, sunitinib)
4
Preference for imaging modality 4 bone scintigraphy
2 PET/CT
4 no preference
Mean dose of 99mTc-MDP 548.9 MBq (range 511–574)
Mean dose of 18F-NaF 253.5 MBq (range 234–274)
Mean time between 99mTc-MDP bone
scintigraphy/SPECT +18F-NaF
PET/CT
8 days (range 3–17)
ECOG, Eastern Cooperative Oncology Group score.
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Following multimodality review, a total of 77 lesions were
diagnosed as malignant (Figure 1 and supplementary Table S2,
available at Annals of Oncology online). 77/77 of these were
identiﬁed by 18F-NaF PET/CT [100%; 95% conﬁdence intervals
(CI) 95.2% to 100%], 35/77 by CT alone (45.5%; 95% CI 34.8%
to 56.5%) and 22/77 by 99mTc-MDP bone scintigraphy/SPECT
(28.6%; 95% CI 19.7% to 39.5%). The sensitivity of 18F-NaF
PET/CT was more than double that of CT alone and three times
more than that of 99mTc-MDP bone scintigraphy/SPECT. CT
and bone scintigraphy together, which reﬂects standard-of-care
imaging for patients with suspected bone metastases, identiﬁed
50/77 of the metastases reported by 18F-NaF PET/CT (65%;
95% CI 53.8% to 74.7%).
On an individual patient basis, 18F-NaF PET/CT also detected
more RCC metastases compared with 99mTc-MDP bone
scintigraphy/SPECT or CT alone (P = 0.007). There was no sig-
niﬁcant difference in the mean number of lesions found
between CT and 99mTc-MDP bone scintigraphy (incident risk
ratio 1.591; 95% CI 0.940–2.691; P = 0.084); however, 18F-NaF
PET/CT found signiﬁcantly more lesions than 99mTc-MDP
bone scintigraphy (incident risk ratio 3.500; 95% CI 2.194–
5.584; P < 0.001) and CT alone (incident risk ratio 2.200; 95%
CI 1.484–3.262; P < 0.001). 18F-NaF PET/CT detected more me-
tastases compared with the other modalities irrespective of
patient performance status [Eastern Cooperative Oncology
Group scores (ECOG); Table 1].
The average time to report the imaging was 14.5 min (range
10–20 min) for 99mTc-MDP bone scintigraphy/SPECT, 11.0
min (range 9–17 min) for CT and 20.0 min (range 8–40 min)
for 18F-NaF PET/CT.
discrepancies and follow-up imaging
All 10 patients had follow-up CT imaging which was used to
evaluate discrepancies between imaging modalities. Twenty-
three lesions were only identiﬁed on 18F-NaF PET/CT
(Figure 1F–J); 19 of these lesions were subsequently identiﬁed as
malignant lesions on standard-of-care bone scintigraphy [6],
CT [8] or magnetic resonance imaging (MRI) [5]. Three of the
remaining lesions were in the extremities and were not included
on follow-up imaging. The fourth lesion, in the femoral head,
was stable on follow-up imaging and could represent a treated
metastasis or a benign lesion.
For 10/77 lesions, there was intermodality disagreement on
the malignant/benign nature of the lesions and a consensus
could not be reached even after multimodality review (supple-
mentary Table S3, available at Annals of Oncology online). Of
the 10 discrepancies, 3 lesions were in the pelvis, 2 in vertebral
bodies, 2 in the skull and 3 in the long bones. Seven of the 10
lesions were imaged on follow-up, and all were diagnosed as
malignant. In addition, one metastasis was found on follow-up
imaging that had not been reported by the trial 18F-NaF PET/
CT: a patient developed a pathological clavicle fracture that,
in retrospect, could be identiﬁed on the trial 18F-NaF PET/CT
and had been missed at the time of reporting. Although this
study was not designed to assess the true sensitivity, the relative
sensitivities revised to reﬂect this extra metastasis are as
follows: 18F-NaF PET/CT: 98.7% (95% CI 93.1% to 99.9%); CT
alone: 44.9% (95% CI 34.3% to 55.9%) and 99mTc-MDP bone
scintigraphy/SPECT: 28.2% (95% CI 19.4% to 39.0%).
lesion characteristics
The majority of metastases were lytic and showed high tracer
uptake (supplementary Table S2, available at Annals of Oncology
online). Sclerotic metastases were found in three patients imaged
following treatment. Seven of the 77 lesions reported on 18F-NaF
PET/CT were only identiﬁed on the CT component.
Quantitative analysis was carried out on 35 benign lesions
(score 1–2) and 66 malignant lesions (score 4–5); some lesions
could not be analyzed quantitatively due to their small size or
location. Malignant lesions were signiﬁcantly larger than benign
lesions (P < 0.001): the median volume of the malignant lesions
was 0.6 cm3 (range 0.1–5.1 cm3) and of the benign lesions was
0.3 cm3 (range 0.1–2.8 cm3). The mean difference in volume
A
D E
F G H
B C
I J
Figure 1. (A–C) Lesion in the right ilium detected by all three modalities:
(A) axial 99mTc-MDP SPECT; (B) axial CT; (C) axial 18F-NaF PET. (D and
E) Example of 18F-NaF PET signal emphasizing a CT abnormality in the left
posterior elements of the L5 vertebral body: (D) axial CT; (E) 18F-NaF PET.
(F–J) Examples of lesions only identiﬁed on 18F-NaF PET/CT. Vertebral me-
tastases: (F) 99mTc-MDP bone scintigraphy coronal image. (G) CT sagittal
reconstruction. (H) 18F-NaF PET sagittal reconstruction showing metastases
with low tracer uptake (arrows). Metastasis in the inferior pubic ramus: (I)
axial CT image; (J) 18F-NaF PET image.
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(log-scale) between benign and malignant lesions was 0.71 (95%
CI 0.36 to 1.06; P < 0.001). The malignant lesions also showed a
signiﬁcantly higher SUVmax and SUVmean (P < 0.001): the
median SUVmax for the malignant lesions was 12.4 (range 4.4–
38.3) compared with 10.1 for the benign lesions (range 2.5–
25.3); the median SUVmean for the malignant lesions was 11
(range 3.8–31.5) compared with 8.4 for the benign lesions
(range 2.2–21.2). The mean difference in SUVmax (log-scale) was
0.54 (95% CI 0.32 to 0.76; P < 0.001). The mean difference in
SUVmean (log-scale) was 0.55 (95% CI 0.33 to 0.77; P < 0.001).
discussion
Previous studies comparing bone scintigraphy, 18F-NaF PET/
CT, 18F-FDG PET/CT and MRI for the detection of skeletal me-
tastases have found 18F-NaF PET/CT to be superior for the de-
tection of these metastases across a broad range of cancers [9,
10, 13, 14]. This work represents the ﬁrst prospective study of
the role of 18F-NaF PET/CT in metastatic RCC in conjunction
with an adaptive trial design.
18F-NaF PET/CT demonstrated a signiﬁcant number of me-
tastases that were occult on standard-of-care imaging. The tech-
nique is more than twice as sensitive at detecting RCC bone
metastases compared with CT alone and more than three times
as sensitive compared with 99mTc-MDP bone scintigraphy with
pelvic SPECT. Collectively, CT and bone scintigraphy only iden-
tiﬁed 65% of the metastases identiﬁed by 18F-NaF PET/CT. The
increased sensitivity of 18F-NaF PET/CT could be used to detect
occult metastases in patients considered to have no bone metas-
tases with current standard-of-care imaging if identiﬁcation of
these metastases would signiﬁcantly alter patient management.
These results represent the ﬁrst step in addressing whether the
technique can be used to select patients with resectable meta-
static disease not identiﬁed by other imaging techniques, or
patients with signiﬁcant occult bone metastases which renders
them unsuitable for surgery. The technique could also be used
as an imaging biomarker for drug development and response to
therapy in the nonoperative and neoadjuvant settings. However,
this trial was powered only to identify the relative sensitivity of
18F-NaF PET/CT in detecting bone metastases in a population
with known metastases. Other potential roles of the technique
may be investigated in large multicenter trials in the future.
A limitation of this study is the lack of a gold standard for
true metastases. The speciﬁcity of 18F-NaF PET/CT could not
be determined as it was not feasible to verify all the lesions by
biopsy due to the large number of lesions and the complexity of
PET-guided biopsy. However, subsequent standard-of-care
imaging detected 19 of the 23 lesions that were only detected by
18F-NaF PET/CT in the trial setting, showing that these lesions
were correctly identiﬁed as malignant. Only four lesions were
not veriﬁed as metastases on follow-up imaging; three lesions
were outside of the imaged ﬁeld and the fourth stable lesion
could represent a treated metastasis or a benign lesion. No false
positives were identiﬁed. Only one missed metastasis was found
on follow-up imaging, which represented a reporting error
rather than a true limitation of 18F-NaF PET/CT.
Intermodality disagreement was most common at sites with
overlapping structures such as in the pelvis and vertebrae,
leading to uncertainty as to whether small lesions are
degenerative or malignant. In the skull, it can be difﬁcult to dif-
ferentiate metastases from normal variants, such as arachnoid
granulations and venous lakes, or benign lesions. Quantitative
analysis of the 18F-NaF PET data identiﬁed characteristics that
may help to distinguish benign from malignant lesions where
there is diagnostic uncertainty: the metabolic volume and tracer
uptake of the malignant lesions was found to be signiﬁcantly
greater than that for the benign lesions. These features could be
used in the clinical setting to aid diagnosis.
Although the trial was not speciﬁcally powered to address the
relationship between the evaluation of bone metastases and
ECOG score, it is interesting to note that 18F-NaF PET/CT
detected more metastases even in patients with good perform-
ance status. While there have been previous studies evaluating
the role of bone scintigraphy in metastatic renal patients with
low ECOG scores [15], future trials addressing the role of 18F-
NaF PET/CT in this group of patients are now required.
The adaptive study design proved successful in efﬁciently
extracting the results from a small number of patients. Following
a signiﬁcant result after recruiting only 10 patients, the study was
closed which avoided unnecessary further recruitment. The result
emphasizes the potential role of well-designed adaptive studies in
the context of imaging studies where high patient costs may be
prohibitive for large trials.
There are two published case studies on the use of 18F-NaF
PET/CT for the detection of RCC metastases [16, 17]. The ﬁrst
found that all the lytic lesions on CT demonstrated 18F-NaF
uptake, with ﬁve additional ﬂuoride-avid lesions that were not
seen on CT [16]. The second found that 18F-NaF PET/CT
detected three additional lesions compared with bone scintig-
raphy [17]. Our ﬁndings are supported by a recent pilot study
which showed an increased detection rate of bone metastases
with 18F-NaF PET/CT in 13 patients imaged with 18F-NaF PET/
CT (from skull to thigh only) and bone scintigraphy [18]. Our
prospective study compared whole-body 18F-NaF PET/CT to
bone scintigraphy and CT alone in all patients and demon-
strated the statistically signiﬁcant superiority of 18F-NaF PET/
CT over current routine imaging modalities.
Compared with 99mTc-MDP, 18F-NaF has several advantages
including rapid bone uptake and blood clearance, it can be
imaged within an hour of i.v. administration, and it has an excel-
lent signal-to-noise ratio [7, 8]. The radiation dose from 250 MBq
of 18F-NaF (6 mSv) is similar to that from 600 MBq of 99mTc-
MDP (3 mSv). The high-resolution full-body CT component of
the PET/CT has an associated dose of 16 mSv; as CT imaging is
routinely carried out as part of standard-of-care imaging, this
could be combined with the PET imaging for attenuation correc-
tion. Although the PET/CT took longer to report than the other
two techniques, this was only 5 min more than that for bone scin-
tigraphy and 9 min more than that for CT. On a practical level,
there have been shortages of the precursor to 99mTc, molyb-
denum-99, which makes alternative radionuclides increasingly
important to maintain a clinical service for the detection of bone
metastases [19].
Our study is the ﬁrst prospective trial comparing 18F-NaF
PET/CT imaging to 99mTc-MDP bone scintigraphy and CT
alone for detecting RCC bone metastases. 18F-NaF PET/CT was
found to be superior at detecting metastases compared with the
other techniques, and detected a number of metastases that were
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not identiﬁed by standard-of-care imaging. The detection of
these occult metastases can signiﬁcantly alter the management
of patients who are diagnosed as being metastasis free with
standard-of-care imaging, for example those being assessed for
surgery with curative intent. Guidelines for the imaging of
patients with RCC should consider inclusion of 18F-NaF PET/
CT for bone metastases.
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